Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07852910
Starting soon Not applicable

Indoor Overheating and Physiological Strain in Older Adults With COPD

NCT07852910 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-10-13
Last updated
2026-10-01

Condition(s) studied

Chronic Obstructive Pulmonary Disease (COPD)Heat Stress

Investigational drug(s) / intervention(s)

Simulated indoor thermal environment

Simulated indoor thermal environment: Day-long (8 h) passive exposure in a climate-controlled environmental chamber at a set air temperature and relative humidity. Participants remain seated or resting.

Study summary

During warm weather, homes without air conditioning can stay hot for long periods, and most heat-related health problems in Canada happen indoors rather than outdoors. Health Canada recommends that indoor temperatures not exceed 26 °C in homes occupied by people who are more susceptible to heat. That recommendation is based largely on population-level evidence, and very little is known about how susceptible individuals actually respond, physiologically, when indoor temperatures rise above it.

Older adults living with chronic obstructive pulmonary disease (COPD) are among the groups identified as more susceptible to heat. COPD involves persistent airflow limitation, reduced lung and cardiovascular reserve, and altered cellular stress responses. Despite this, no laboratory study has directly measured how adults with COPD respond to a full day spent indoors in warm conditions.

This randomized crossover trial will measure how older adults with COPD respond to two different indoor environments, each experienced for eight hours on separate days at least one week apart. One day is spent at the recommended indoor temperature limit and the other at a warmer temperature representative of conditions recorded inside Canadian homes during hot weather. Participants remain seated and rest throughout; no exercise or work is performed.

Throughout each day, the research team continuously measures core body temperature, skin temperature, heart rate, and measures blood pressure, lung function, breathlessness, thermal comfort, cognitive performance, and balance at set time points. Blood and urine samples are collected at the start and end of each day. Participants are monitored continuously by trained staff.

The results are intended to strengthen the evidence base behind Canadian indoor temperature guidance and to inform recommendations for protecting people living with chronic lung disease during hot weather.

Eligibility

Sex
ALL
Min age
60 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 60 to 80 years * Physician diagnosis of chronic obstructive pulmonary disease made at least 5 years previously * Clinically stable, with no acute exacerbation or active respiratory infection in the preceding 6 weeks * Current non-smoker * Able to communicate in English or French and to provide written informed consent Exclusion Criteria: * Physical restriction preventing safe participation, including unstable cardiac or pulmonary disease, uncontrolled hypertension (resting blood pressure exceeding 150/95 mmHg), severe arthritis, renal impairment, active proliferative retinopathy, history of disabling stroke, or intermittent claudication * Recent change in medications judged by the investigators to make participation inadvisable * Cardiac abnormalities identified on electrocardiogram during the screening exercise test * Regular work or exercise in hot environments (heat acclimatized)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Ottawa Ottawa Ontario

More University of Ottawa trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07852910 on ClinicalTrials.gov ↗ ← All trials in Canada